January 15, 2019
Kudos ...
| |
 |
|
 |
| |
Shelle Bryant |
|
Jenny Anderson |
... to Shelle Bryant and Jenny Anderson for leading all planning and organizational efforts for the 2018 CFAR National Meeting. What they did was challenging, ambitious, crucial, intricate, exacting, herculean ... and utterly and completely successful.
Yay Team!
Rising Stars...
ESI Poster Presenters
Twenty three Early Stage Investigators from around the country were competitively chosen to present posters in keeping with this year's National Meeting theme:
"From Bench: Basic Science
To Bedside: Clinical Science
To Our Own Backyard": Social/Behavioral Science
Focus On...
The CFAR National Symposium
Click each link to watch the
associated videos.
Opening Remarks
(begins at the 3:13 mark)
(3:30)
Keynote Part I: Ending the HIV/AIDS Pandemic:
The Critical Role of HIV Prevention Science
(24:50)
Keynote Part II: CDC Global and Domestic
Infectious Disease Priorities
(begins at the 33:10 mark)
(28:07)
Q&A with Drs Faucci & Redfield
(begins at the 1:02:07 mark)
(17:28)
Session 1: HIV in the South — Living and Providing Care in the Epicenter
The HIV Epidemic in the South
(begins at the 1:25 mark)
(14.14)
Exploring Medical Systems as Part of the 'Social Context' when Patients Navigate the HIV Treatment Cascade
(begins at the 15:57 mark)
(26.58)
Improving the Care Continuum in Atlanta:
Lessons from the Front
(begins at the 43:05 mark)
(20:54)
Session 1 Q&A with Drs McCray, Malebranche & Armstrong
(begins at the 1:04:00 mark)
(12:30)
Research Participant Panel
(begins at the 1:16:40 mark)
(23:00)
Session 2: The Final Frontiers in HIV Research — Developing an Effective Vaccine & Achieving a Cure
Antibody-based therapeutics: Hit Early, Hit Hard
(26.44)
Immune-based strategies targeting viral persistence
in SIV-infected macaques
(begins at the 27:00 mark)
(22:35)
Oral Abstract 1: Relationship between rebound and latent viruses in a clinical trial of anti-HIV-1 antibody 3BNC117
(begins at the 49:40 mark)
(9:38)
Oral Abstract 2: Anti-apoptotic protein BIRC5 maintains survival in HIV-1 infected CD4 T cells
(begins at the 59:20 mark)
(10:26)
Oral Abstract 3: Sequence Entropy-Guided Excision of HIV using Enhanced CRISPR/Cas9 and Polycistronic Multiplexing
(begins at the 1:09:50 mark)
(14:10)
Session 2 Q&A with Drs. Haigwood, Paiardini, Cohen,
Kuo, and Chavez
(begins at the 1:24:07 mark)
(4:50)
Session 3: Tackling Syndemics — Identifying Solutions to the Persistent Crisis of Substance Abuse and HIV
Medications for Opioid Use Disorder to Improve the HIV Continuum of Care
(25:23)
How the abuse of cocaine (and other stimulants) perpetuates the HIV epidemic in the American South
(begins at the 26:16 mark)
(20:00)
Potential for HIV Outbreaks in Rural Kentucky
(begins at the 46:22 mark)
(24:01)
Session 4: No Population Left Behind: Getting to 90:90:90 for All
Biomedical Prevention of HIV-1 Infection in Women:
As Simple as Daily Oral PrEP?
(24:56)
Improving the Cascade of Care for Key Populations:
MSM and PWID Advances
(begins at the 25:09 mark)
(22:07)
Oral Abstract 1: Ecological Factors and Sexual Health Outcomes in US Black MSM
(begins at the 47:20 mark)
(10:10)
Oral Abstract 2: Low rates of Postpartum Retention in Care and Viral Suppression among HIV‐Infected
Women in Mississippi
(begins at the 57:40 mark)
(10:50)
Oral Abstract 3: HIV cascade of care outcomes cluster spatially among female sex workers in Iringa, Tanzania
(begins at the 1:08:38 mark)
(12:04)
Closing Plenary
Current State of HIV Research:
The View from PEPFAR
(40:35)
Final Remarks
(begins at the 40:40 mark)
(4:59)
| 
Are you on Twitter? Follow us here
